IDSA关于ESBL-E、CRE及难治耐药铜绿假单胞菌感染治疗指南
美国感染病学会(IDSA)6名耐药感染专家组成小组,基于已发表文献与临床经验,针对产超广谱β-内酰胺酶肠杆菌目(ESBL-E)、碳青霉烯耐药肠杆菌目(CRE)及难治耐药铜绿假单胞菌(DTR-P. aeruginosa)感染提出治疗推荐。指南聚焦美国耐药分子流行病学与药物可及性,涵盖经验性治疗选择、疗程及优选与替代方案,适用于成人与儿童,截至2020年9月17日。
要点
- 针对ESBL-E、CRE和DTR-P. aeruginosa感染给出优选与替代治疗推荐
- 推荐假定病原体已明确且药敏结果已知,适用于成人与儿童
- 耐药领域进展迅速,指南将定期更新并扩展至其他革兰阴性耐药菌
核心结论
- 该指南为ESBL-E、CRE和DTR-P. aeruginosa感染提供治疗推荐,并指出耐药领域动态快速演变、治疗将持续挑战临床医生。
- 指南当前版本截至2020年9月17日,将随新数据定期更新,并计划在未来版本扩展至其他问题革兰阴性病原体。
研究设计与样本
- 由6名擅长管理耐药感染的感染病专家组成小组,基于已发表文献复习与临床经验,针对ESBL-E、CRE和DTR-P. aeruginosa治疗的常见问题提出推荐及理由。
- 因全球耐药分子流行病学与特定抗感染药物可及性差异显著,本文件聚焦美国耐药感染的治疗。
主要发现
- 文中简要讨论经验性治疗选择、疗程及其他管理考量。
- 大部分推荐内容聚焦于假定致病菌已鉴定且药敏试验结果已知情况下的优选与替代治疗推荐。
- 治疗推荐同时适用于成人与儿童。
临床怎么用
- 临床可在致病菌已明确、药敏结果已知时,参照本指南选择ESBL-E、CRE和DTR-P. aeruginosa感染的优选或替代治疗方案。
- 经验性治疗选择、疗程等管理考量可参考文中简要讨论。
局限性
- 指南聚焦美国耐药流行病学与药物可及性,全球其他地区适用性受限。
- 推荐主要针对已明确病原体且药敏结果已知的情形,经验性治疗内容讨论较简略。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Antimicrobial-resistant infections are commonly encountered in US hospitals and result in significant morbidity and mortality. This guidance document provides recommendations for the treatment of infections caused by extended-spectrum β-lactamase-producing Enterobacterales (ESBL-E), carbapenem-resistant Enterobacterales (CRE), and Pseudomonas aeruginosa with difficult-to-treat resistance (DTR-P. aeruginosa). METHODS: A panel of 6 infectious diseases specialists with expertise in managing antimicrobial-resistant infections formulated common questions regarding the treatment of ESBL-E, CRE, and DTR-P. aeruginosa infections. Based on review of the published literature and clinical experience, the panel provide recommendations and associated rationale for each recommendation. Because of significant differences in the molecular epidemiology of resistance and the availability of specific anti-infective agents globally, this document focuses on treatment of antimicrobial-resistant infections in the United States. RESULTS: Approaches to empiric treatment selection, duration of therapy, and other management considerations are briefly discussed. The majority of guidance focuses on preferred and alternative treatment recommendations for antimicrobial-resistant infections, assuming that the causative organism has been identified and antibiotic susceptibility testing results are known. Treatment recommendations apply to both adults and children. CONCLUSIONS: The field of antimicrobial resistance is dynamic and rapidly evolving, and the treatment of antimicrobial-resistant infections will continue to challenge clinicians. This guidance document is current as of 17 September 2020. Updates to this guidance document will occur periodically as new data emerge. Furthermore, the panel will expand recommendations to include other problematic gram-negative pathogens in future versions. The most current version of the guidance including the date of publication can be found at www.idsociety.org/practice-guideline/amr-guidance/.
引用
- Tamma PD, Aitken SL, Bonomo RA, et al. Infectious Diseases Society of America Guidance on the Treatment of Extended-Spectrum β-lactamase Producing Enterobacterales (ESBL-E), Carbapenem-Resistant Enterobacterales (CRE), and Pseudomonas aeruginosa with Difficult-to-Treat Resistance (DTR-P. aeruginosa). Clin Infect Dis. 2021. PMID: 33830222. doi:10.1093/cid/ciab295
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。